Clinical trial on shock wave treatment for wounds gets a boost from Swift

November 14, 2018|Clinical News

TORONTO, CANADA (WEDNESDAY, NOVEMBER 13th, 2018)  Swift Medical Inc., has successfully demonstrated the critical necessity of accurate and reliable wound measurement in research on chronic wound therapy.

In a joint study by Wroclaw Medical University in Wroclaw, Poland and the University of Manitoba in Winnipeg, Canada, researchers used extracorporeal shock wave (ESW) therapy to accelerate the healing of pressure ulcers. The research team tracked the wound healing progression with Swift Skin and Wound, the world’s most advanced and comprehensive digital wound care management software.

“We found that Swift Skin and Wound provided accurate and reliable measurements,” says Robert Dymarek, a scientist at Wroclaw Medical University’s department of nervous system diseases. “We believe that use of such a tool is incredibly valuable in the context of a clinical trial.”

Dr. Yunghan Au, VP medical affairs at Swift, notes that the ESW study marks the first time Swift Skin and Wound was used in a clinical trial to measure the outcomes for a direct medical intervention.

“And it won’t be the last,” he says. “With the accuracy and reliability of wound measurements achieved with Swift Skin and Wound, it’s clear that clinical researchers working on new treatments modalities need objective and traceable methods to support and validate their work on wound treatments.

Used by more than 1,000 facilities in the United States and Canada, Swift Skin and Wound captures wound images and data without touching the wound through its smartphone-ready Swift App and the Swift HealX, an FDA-registered marker to calibrate wound images for size, color and lighting. Swift Skin and Wound also features Swift Dashboards, which provide real-time views of critical data such as patients at risk of deteriorating or developing new wounds.

The results of the study provide an early indication of the clinical value of ESW treatment of wounds such as pressure ulcers. The researchers plan further clinical trials for this new treatment modality in chronic wounds.

“Given that Swift Skin and Wound is also used by healthcare providers, it would be powerful in the future to align outcome measures used in trials with those in real-world settings,” adds Dr. Dymarek, who co-presented the joint study’s findings at the At the 20th annual meeting of the European Pressure Ulcer Advisory Panel (EPUAP), held last September in Rome. “This would further validate the value of technological interventions in wound care.”

For more information or to schedule media interviews contact:

Yan Zhou, Manager, Media Relations, MaRS Ventures
647.354.2547
yzhou@marsdd.com

About Swift Medical
Swift Medical is the world leader in digital wound care management, delivering advanced wound care visualization and touchless 3D measurement through its smartphone-ready Swift Skin and Wound software. This enterprise-grade solution streamlines clinical and administrative wound care management workflows, from image capture and automatic risk scoring to assessment scheduling and claims submission. Today, Swift Skin and Wound is in use by more than 1,000 facilities to monitor over 100,000 beds. To learn how Swift has digitized and transformed wound care, visit swiftmedical.com.

Subscribe for Email Updates